Integrated Biopharma

Integrated Biopharma Interest Expense

The Interest Expense of Integrated Biopharma (INBP) as of Nov 6, 2026 is 39,000.00 USD. In the previous year, Interest Expense was 18,000.00 USD — a change of 116.67% (higher).

Interest Expense

39,000.00USD

YoY

116.67%

Last updated:

Interest Expense of Integrated Biopharma is 2025 39,000.00 USD. Interest Expense of Integrated Biopharma was 2024 18,000.00 USD. It decreases by 116.67% higher compared to the previous year.

The Integrated Biopharma Interest Expense history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Expense
Date
Interest Expense
Jan 1, 2018
-430,000.00 USD
Jan 1, 2019
-640,000.00 USD
Jan 1, 2020
-220,000.00 USD
Jan 1, 2021
-250,000.00 USD
Jan 1, 2022
-180,000.00 USD
Jan 1, 2023
-60,000.00 USD
Jan 1, 2024
18,000.00 USD
Jan 1, 2025
39,000.00 USD
The Integrated Biopharma Interest Expense history
YEARInterest ExpenseYoY
39,000.00USD+116.67%
18,000.00USD-130.00%
-60,000.00USD-66.67%
-180,000.00USD-28.00%
-250,000.00USD+13.64%
-220,000.00USD-65.63%
-640,000.00USD+48.84%
-430,000.00USD-67.91%
-1.34 MUSD+31.37%
-1.02 MUSD+277.78%
-270,000.00USD-72.73%
-990,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Integrated Biopharma Stock analysis

What does Integrated Biopharma do? Integrated Biopharma Inc. is a New York-based company specializing in the development, manufacturing, and marketing of health products. Founded in 1979, the company has acquired extensive experience in the industry. Integrated Biopharma's business activities encompass four main areas: biopharmaceuticals, pharmaceuticals, dietary supplements, and veterinary products. Each of these divisions is focused on the development and manufacturing of specific products, contributing to the overall business of the company. In the biopharmaceuticals sector, the company focuses on developing therapeutic products for rare and severe diseases. The product development is carried out in close collaboration with the Columbia University Medical School. In the pharmaceuticals sector, Integrated Biopharma produces generics as well as its own products targeting the treatment of diabetes, cancer, and cardiovascular diseases, among others. Dietary supplements are also part of Integrated Biopharma's product portfolio, with a focus on manufacturing vitamin and mineral supplements, as well as herbal dietary supplements. Additionally, the company offers a variety of veterinary products, including preparations for the health of domestic and farm animals, as well as medications for the treatment of animal diseases. One important business model of Integrated Biopharma is the manufacturing and marketing of mostly patent-free, yet high-quality products. Furthermore, the company collaborates closely with other companies and institutions to develop new products and technologies. Another important strategy of Integrated Biopharma is to market its products worldwide. The company has distribution partners in many countries, including China, Canada, Mexico, France, and Germany. Integrated Biopharma places a strong emphasis on the highest quality standards and therefore invests in modern infrastructure and a well-trained workforce. The company operates its own production facilities and research institutions in the USA and China. Among Integrated Biopharma's most well-known products are the diabetes medication "GlipiZIDE," the carcinoma medication "Paclitaxel," and the veterinary antibiotic "Gentamicin Sulfate." Overall, Integrated Biopharma has received numerous awards and certifications for its products and business activities in recent years. The high quality and effectiveness of its preparations, as well as its responsible approach to resources and the environment, make Integrated Biopharma an important player in the healthcare industry. Integrated Biopharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Integrated Biopharma stock

Interest Expense of Integrated Biopharma is 39,000.00 USD in 2025.

Interest Expense of Integrated Biopharma changed from 18,000.00 USD to 39,000.00 USD, representing a 116.67% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Interest Expense Integrated Biopharma since 2006 – with annual values, charts, and detailed analysis.

Interest expense represents the cost of borrowing. Higher interest expenses can indicate a highly leveraged company.

Interest Expense's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Interest Expense's Integrated Biopharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Integrated Biopharma

All Key Metrics — Integrated Biopharma